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Abstract 
 
Leishmaniasis is a neglected tropical disease responsible for the ninth largest disease burden in 
the world threatening 350 million people mostly in developing countries. The lack of efficacy, 
severe adverse effects, long duration, high cost and parenteral administration of the current 
therapies result in poor patient compliance and emergence of resistance. Leishmaniasis’ unmet 
need for safer, affordable and more effective treatments is only partly addressed by today’s 
global health product pipeline that focuses on products amenable to rapid clinical development, 
mainly by reformulating or repurposing existing drugs for new uses. Excipients are necessary 
for ensuring the stability and bioavailability of currently available antileishmaniasis drugs 
which in their majority are poorly soluble or have severe side-effects. Thus, selection of 
excipients that can ensure bioavailability and safety as well as elicit a synergistic effect against 
the Leishmania parasites without compromising safety will result in a more efficacious, safe 
and fast to market medicine. We have evaluated the in vitro activity of 30 commercially 
available generally regarded as safe (GRAS) excipients against different Leishmania spp., their 
cytotoxicity and potential use for inclusion in novel formulations. Amongst the tested 
excipients, the compounds with higher selectivity index were Eudragit E100 (cationic triblock 
copolymer of dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate), 
CTAB (cetyltrimethylammonium bromide, cationic), lauric acid, Labrasol (non-ionic, 
caprylocaproyl polyoxyl-8 glycerides) and sodium deoxycholate. An ideal excipient need to 
possess amphiphilic nature with ionic/polar groups and possess a short or medium fatty acid 
chain such as lauric (C12), capric (C10) or caprylic acid (C8).  Inclusion of these excipients 
and identification of the optimal combination of drug and excipients would lead to a more 
effective and safer antileishmanial therapies. 
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1. Introduction 
 
Leishmaniasis is a neglected tropical disease responsible for the ninth largest disease burden 
[1]. Currently, leishmaniasis threatens 350 million men, women and children in 88 endemic 
areas around the world, 72 of which are developing countries with limited healthcare budgets 
[2]. The three major manifestations of the disease are: visceral (VL), cutaneous (CL) and 
mucocutaneous (MCL) leishmaniasis. CL new cases are estimated to range from 0.7 to 1.3 
million while VL new cases range between 0.2 to 0.4 million according to the World Health 
Organisation (WHO) [3]. Patients illustrate clinical symptoms ranging from simple cutaneous 
lesions to mucocutaneous ulcers or systemic disease affecting vital body organs such as the 
liver and spleen or show a confounded severe clinical manifestation complicated by other co-
infections such as HIV/AIDS [4]. The fatality rate of VL can be as high as 100% within two 
years if left untreated and the disease is characterised by fever, weight loss, anaemia and 
swelling of the spleen and liver (where parasites are located in high amounts and replicate) [2]. 
Although fatality rate of CL or MCL is lower compared to VL, the skin and mucous membrane 
lesions are debilitating resulting in serious disability and stigma leaving patients permanently 
scarred, unable to be employed and sometimes casted out from society [2, 3]. 
The therapeutic arsenal to treat leishmaniasis is far from ideal. Pentavalent antimonials 
including sodium stibogluconate (SSG) and N-methylglucamine antimoniate (meglumine 
antimoniate) remain the first line treatment for VL (Table 1) [5]. As resistance to antimonials 
is becoming more common limiting their use, emerging second-line treatments involve 
pentamidine and Amphotericin B (AmB). AmB administered parenterally is highly effective 
in VL and is available as an affordable micellar formulation (Fungizone®) which is highly 
nephrotoxic limiting the dose able to be administered [6], a liposomal formulation 
(Ambisome®) which is the first line treatment in the developed world,  and lipidic complexes 
(Amphocil® and Abelcet®) whose use is limited further by their cost compared to Ambisome®. 
Cost of therapy with AmB is also further increased by the need for cold transport and 
refrigeration. This has led to the clinical use of heated Fungizone® in India (prepared by 10-
fold dilution with water and heating to 70oC for 20 minutes [7]) which results in larger AmB 
aggregates that are not cleared by the kidneys effectively reducing observed nephrotoxicity [8]. 
Pentamidine, another second-line drug, has been shown to cause insulin dependent diabetes 
which is irreversible and potentially fatal [8]. 
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Although many research efforts are focused on developing an oral amphotericin B formulation, 
no oral formulations are currently marketed due to its poor aqueous solubility and permeability 
across biological barriers [6, 9, 10]. Other clinically used medicines for leishmaniasis include 
paromomycin (characterised by its low cost but variable efficacy) and miltefosine. The latter, 
which was first licensed in India in 2003 as the first oral licensed treatment, possesses a long 
elimination half-life (7 days) and a narrow therapeutic index limiting the dose administered 
allowing for subtherapeutic levels to remain for several weeks encouraging the emergence of 
resistance [11]. This has already been observed  in India (Bihar region that accounts alone for 
50% of VL worldwide burden) and France [12].  Miltefosine has also known teratogenic effects 
which limits its use in women of child-bearing age and pregnant women [13]. 
As there is no effective vaccine for any of the ten WHO identified neglected tropical diseases 
including Leishmania, there is an unmet need for enhancing the efficacy, safety, compliance 
and affordability of available therapies as well a need to develop new medicines.  To achieve 
this, ideally new chemical entities (NCEs) are required with enhanced potency, specificity, and 
lack of toxicity in order to provide breakthrough therapeutic benefits within a wide safety 
margin. However, they are riskier to invent than expanding the use of existing drugs by either 
repurposing or reformulating them or by combining them in novel fixed-dose combinations 
with enhanced efficacy and reduced duration of treatment.   
Excipients are components of a finished drug product other than the active pharmaceutical 
ingredient (API) and are added during formulation for well-defined functions that can vary 
from facilitating the manufacture process (such as diluents, binders, lubricants), protecting the 
drug from physicochemical degradation (stabilisers, antioxidants), improving the 
bioavailability of the API (solubility and permeability across biological membranes, targeting, 
controlled-release). However, excipients could potentially work synergistically with the API 
resulting in an enhanced overall efficacy and safety of the medicine. In this study, we explore 
this hypothesis by assessing the in vitro activity against Leishmania spp. of 30 commercially 
available excipients and their cytotoxicity in order to evaluate their potential for inclusion in 
novel engineered dosage forms against leishmaniasis. 
 
2. Materials and methods 
2.1. Materials 
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Soy phosphatidylcholine (Lipoid® S 100, Batch 790611-03/906) was obtained from Lipoid 
GmbH (Ludwigshafen Germany). DOTAP-CL (1,2-dioleoyl-3-trimethylammonium propane) 
and C18:0 PEG2000 PE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine, N-[methoxy-
(polyethylene glycol)-2000], ammonium salt) were bought from Avanti® Polars Lipids 
(Alabama, USA). Tripalmitin (99% pure, Batch A009787) was purchased from Acros® 
Organics (Geel, Belgium). Beta-cyclodextrin (Cavamax® W7, Batch 70P470), hydroxypropyl-
beta-cyclodextrin (Cavasol® W7 HP, Batch 73B025) and gamma-cyclodextrin (Cavamax® W8, 
Batch 80P241) were donated from Wacker Chemie AG (Munchen, Germany). Sodium 
deoxycholate (Batch: 30970) and hexadecyl trimethylammonium bromide (CTAB, Batch 
H9151) was obtained from Sigma-Aldrich. Human serum albumin (20% w/w, Batch 
NCAB7EL001, also containing 0.02 M sodium caprylate and 0.02 M acetyltryptophan) was 
obtained from Grifols (Barcelona, Spain). Caprylocaproyl polyoxyl-8 glycerides (Labrasol®, 
Batch 151877), oleoyl polyoxyl-6 glycerides (Labrafil® M1944 CS, Batch 110354) and 
diethylene glycol monoethyl ether (Transcutol® P, Batch 450817010) were a donated from 
Gattefosse (St-Priest, France). Polyvinyl caprolactam–polyvinyl acetate–polyethylene glycol 
graft triblock co-polymer (Soluplus®, Batch 71013547G0),  Poloxamer 407, a nonionic, 
triblock co-polymer consisting of a central hydrophobic block of polypropylene glycol flanked 
by two hydrophilic blocks of polyethylene glycol (Pluronic®-F127, ~ 12.5 kDa, Batch 
15H0651) and 2-hydroxyethyl 12-hydroxyoctadecanoate (Solutol® HS15, Batch 44511588Q0) 
were donated from BASF (Ludwigshafen, Germany). Eudragit® E100 (cationic triblock co-
polymer of dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate) 
and Eudragit® L100 (anionic diblock co-polymer based on methacrylic acic and methyl 
methacrylate) were donated from Evonik (Essen, Germany). Polysorbate 20, polysorbate 80, 
isopropyl myristate, polyethylene glycol 400 and polyethylene glycol 6000 were purchased 
from Panreac (Barcelona, Spain). Glycerol (molecular biology grade) was obtained from 
Fagron Iberica (Barcelona, Spain). Acid degraded glycol chitosan polymers of different 
molecular weights as illustrated in Table 2 were prepared and characterised by Dr Aikaterini 
Lalatsa (University of Portsmouth, Portsmouth, UK) using previously published methods [14]. 
Cell culture media and all other chemicals (>98%) were purchased without further purification 
from Sigma-Aldrich (Dorset, UK).  
2.2. Methods 
The selected excipients were classified into the following categories according to their 
chemical structure and composition, ionic charge, critical micelle concentration (CMC), 
7 
 
micellar size and hydrophilic-lipophilic balance (HLB) (Tables 1-4): i) Phospholipids with 
different ionic charges, ii) lipids (C12-C18), iii) steroids, iv) polysaccharides, v) protein 
carriers, vi) polymers, vii) wetting agents, viii) amphiphiles/surfactants, ix) solubilisers, x) 
solvents.  
2.2.1. Particle size determination   
Micellar size of aqueous dispersions of amphiphiles/surfactants was determined as previously 
described [15]. Excipients were diluted with deionised water (pH 6.5) until a final 
concentration of 100 mg/ml (well above their critical micelle concentration) and probe 
sonicated (Branson Sonifier 250, USA) for 15 min. Mean size (nm) was measured by dynamic 
light scattering using a Zetatrac Ultra (Microtrac Inc, USA) with internal probe (range 0.0008 
- 6.5 microns) using five runs of 60 s per sample and based on the size distribution by volume. 
Prior to measurements, polystyrene standards (diameter = 100 nm) were measured; size results 
were in accordance with the nominal size of the standard particles. 
2.2.2. In vitro efficacy  
Parasites and culture procedure 
L. braziliensis 2903 and L. amazonensis (MHOM/Br/79/Maria) [DRSL1]were kindly provided by 
Professor Alfredo Toraño (Instituto de Salud Carlos III, Madrid). L. donovani (MHOM-IN-80-
DD8) was procured from ATCC (Barcelona, Spain). These Leishmania spp. were selected 
because they elicit both VL (L. donovani) and cutaneous and mucocutaneous leishmaniasis (L. 
brasilensis and L. amazonensis) and also as they have shown a variable in vitro susceptibility 
to drugs in previous studies (L. brasiliensis was more susceptible than L. amazonensis) [16]. 
Promastigotes were cultured in Schneider's Insect medium supplemented with 10% heat-
inactivated foetal bovine serum (FBS, Sigma-Aldrich) and 1000 U/L of penicillin plus 100 
mg/L of streptomycin in 25 mL culture flasks at 26 °C [17]. 
In vitro promastigote susceptibility assays 
The in vitro activity studies were performed as previously described [18, 19]. Briefly, log-
phase promastigotes (2.5 x 105 parasites/well) were cultured in 96-well plastic plates. All 
excipients were dissolved in 0.22µm filtered water at 100 mg/ml concentration except from 
those with poor solubility in water that were dissolved at 100 mg/ml using either in DMSO (for 
all the lipids, phospholipids, cholesterol and α-tocopherol) or in DCM (for both methacrylate 
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polymers). In addition, amphiphiles were probe sonicated for 15 min to ensure complete 
dispersion in deionised water. Further dilutions of the excipients using the above described 
medium were performed and were added up to 200 µL final volume resulting in a final 
concentration of 200, 100, 50, 25, 12.5, 6.25 3.125 and 1.065 μg/ml per well. Growth controls 
were also included. The final solvent (DMSO or DCM) concentrations never exceeded 0.5% 
(v/v) warranting no effect on parasites proliferation or morphology [20]. After 48 h at 26 ºC, 
20 μL of a 2.5 mM resazurin (in 2.5 mM in phosphate buffered solution (PBS), pH 7.4, and 
filtered through 0.22 μm prior use) were added and the plates were returned to the incubator 
for another 3 h. The Relative Fluorescence Units (RFU) (535 nm – 590 nm excitation-emission 
wavelength) were determined in a fluorimeter Infinite 200 (Tecan i-Control, Männedorf, 
Switzerland). Growth inhibition (%) was calculated using Equation 1: 
Growth inhibition (%) = 100 −
RFU treated wells – RFU signal to noise
RFU untreated – RFU signal to noise
 𝑥 100           Eq. 1 
All tests were carried out in triplicate. Miltefosine (≥98%, HPLC) dissolved in DMSO was 
used as the reference drug. The efficacy of each compound was estimated by calculating the 
IC50 (concentration of the compound that produced a 50% reduction in parasites) and GI% 
(percentage of growth inhibition at 200 µg/ml).  
2.2.3. Cytotoxicity studies on murine macrophages 
Cytotoxicity tests were performed only for those excipients that possessed in vitro micromolar 
activity against promastigotes. As previously described, J774 murine macrophages were grown 
in RPMI 1640 medium supplemented with 10% heat-inactivated FBS (30 min at 56 °C), 
penicillin G (100 U/mL) and streptomycin (100 μg/mL) [17]. For the experiments, cells in the 
pre-confluence phase were harvested with 0.03% EDTA-0.05% Trypsin in PBS for 20 minutes. 
Cell cultures were maintained at 37 °C in a humidified environment with 5% CO2 (Hucoa-
Erlöss, Forma Scientific, Ohio, USA). 
The assay was carried out as previously described [16]. J774 macrophages cell lines were 
seeded (5 × 104 cells/well) in 96-well flat-bottom microplates with 100 μL of RPMI 1640 
medium. The cells were allowed to attach for 24 h at 37 °C, 5% CO2, and the medium was 
replaced by different concentrations of the compounds resulting in 200 μL volume with a final 
concentration identical to the one above described. Macrophages were exposed to the 
excipients for 24 h. Growth controls were also included. Afterwards, a volume of 20 μL the 
2.5 mM resazurin solution was added, and plates were incubated for another 3 h to evaluate 
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cell viability. The reduction of resazurin was determined by the fluorescence intensity (535 nm 
excitation wavelength and 590 nm emission wavelength) as in the promastigotes assay. Each 
concentration was assayed three times. Medium and drug controls were used in each test as 
blanksand the background was subtracted. Cytotoxicity of the tested compounds was defined 
as the 50% reduction of cell viability of treated culture cells with respect to untreated cells 
(CC50). The selectivity index (SI) was calculated as expressed in Equation 2 [16]: 
 
SI=  
𝐶𝐶50
𝐼𝐶50
       Eq. 2 
 
3. Results and Discussion 
Selected excipients commonly used in the development of drug formulations and 
nanomedicines were evaluated for their in vitro efficacy against promastigotes of VL and CL 
causing Leishmania spp. with different susceptibility against common antileishmanial drugs 
[21]. Among the selected excipients, the compounds that exhibited the lowest IC50 against L. 
amazonensis were as follows: Eudragit E100 < CTAB < DOTAP-CL < sodium deoxycholate 
~ lauric acid < Labrasol. L. braziliensis and L. donovani was found to be more susceptible to 
excipients than L. amazonensis resulting in lower IC50 for tested compounds. The in vitro 
activity of the excipients against L. braziliensis ranked as follows: Eudragit E100 < CTAB < 
lauric acid < Solutol HS15 < Labrasol < sodium deoxycholate < DOTAP-CL < Tween 20. The 
order of excipients with activity against L donovani follows a similar order to that of L 
amazonensis with the exception of DOTAP-CL that showed no activity at the tested 
concentration and lauric acid that illustrated a higher IC50 (Eudragit E100 < CTAB < sodium 
deoxycholate < Labrasol <   Tween 20 < Solutol HS15 < lauric acid) (Table 5).  The excipients 
illustrating the least cytotoxicity but the higher CC50 values were: stearic acid and Eudragit 
E100 (which showed very limited cytotoxicity at the highest tested concentration) followed by 
non-ionic polyethylene glycol esters (Solutol HS 15, Labrasol), anionic lipids or steroids (lauric 
acid, sodium deoxycholate), cationic amphiphiles (DOTAP-CL, CTAB) and polysorbate 20 
(which was the most cytotoxic compound). The SI indicative of compounds with greater 
activity to toxicity ranked as follows: Eudragit E100 > CTAB > lauric acid > Labrasol and > 
sodium deoxycholate in CL causing Leishmania spp., while the SI index favours sodium 
deoxycholate versus CTAB in VL causing Leishmaniasis spp. (Eudragit E100> sodium 
deoxycholate, lauric acid, polysorbate 20 > Solutol HS 15 > Labrasol >CTAB). 
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 Solutol HS15 showed activity only against L. braziliensis and L.donovani with low 
cytotoxicity. As a pegylated ester of stearic acid, a saturated lipid with limited effect against 
promastigotes (Table 5), this is not surprisingly. However, previous studies have also illustrated 
the efficacy of cationic stearylamine-bearing liposomes against L. donovani by interaction with 
the surface exposed negatively charged phosphatidylserine on leishmania parasites abundant 
in parasitic cell membranes but not in mammalian cells [23-25].  
DOTAP-CL, a cationic phospholipid quaternary ammonium chloride salt, needed higher 
concentrations to elicit a 50% reduction in Leishmania promastigotes in L. braziliensis and L. 
donovani. However, for a cationic and quaternary ammonium amphiphile as CTAB the reverse 
trend was observed. The presence of a quaternary ammonium moiety ionised in physiological 
pH as observed within CTAB and DOTAP-CL as well the orally bioavailable miltefosine has 
been implicated for efficacy against Leishmania and Plasmodium protozoa [22]. Although the 
specific mechanism of action of miltefosine against Leishmania spp. is not fully understood, 
the mode of action of this drug is likely to be very similar as its mechanism of action against 
human cancer cells linking its activity mainly to apoptosis (producing reactive oxygen species 
resulting in DNA fragmentation, nuclear condensation and loss of cell volume), but also 
disturbance of membrane lipids (inhibition of phosphatidylcholine and sphingomyelin 
biosynthesis and ether-lipid metabolism) and inhibition of cythochrome c oxidase [26-28]. The 
difference in activity between DOTAP-CL and CTAB can also be explained by the fact that 
quaternary ammonium bromides have been shown to be more active against parasites 
compared to quaternary ammonium chloride salts [22, 29].  Activity of quaternary ammonium 
compounds can be related with its ability to inhibit water permeation through aquaporins which 
leads to cell death [30]. Thus, DOTAP-CL will need to be present in high amounts in liposomes 
or bilosomes for an antileishmanial dosage form if at all useful for a VL medicine [31]. 
Ionic surfactants cause disruption of the cell membrane integrity with cationic surfactants being 
the most cytotoxic followed by anionic and then non-ionic surfactants [32]. This is supported 
by the higher CC50 value of sodium deoxycholate compared to cationic CTAB and DOTAP-
CL [33], as cationic surfactants are known to promote destabilisation of DNA [33]. Anionic 
amphiphiles such as sodium deoxycholate have also shown activity against Leishmania 
protozoa (Table 5, IC50: 134  µM) and when included in Fungizone
® enhance dramatically the 
aqueous solubility of amphotericin B by entrapment within micelles and formation of ion pairs 
[34]. Fungizone has an amphotericin B to deoxycholate ratio of 1:2. Amphotericin B 
deoxycholate systems consist of aggregates of amphotericin B-deoxycholate mixed micelles 
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co-existing with pure deoxycholate micelles. When the deoxycholate concentration is 
subcritical for micellar formation, mixed micelles with amphotericin B are formed first as a 
result of the penetration of the deoxycholate molecules into the amphotericin B micelles. At 
higher concentrations of the surfactant molecules, the micellar structure is completely disrupted 
and amphotericin B is found as a monomer bound to deoxycholate. When the concentration of 
the surfactant is increased even further, micelles of the surfactant molecules built up. Similar 
results were also reported for laurylsucrose [35] and a polyoxyethylene glycol derivative of 
steraric acid (MYRJ 59) [36], although interaction of amphotericin B with laurylsucrose was 
stronger than that of sodium deoxycholate [37]. Both sodium deoxycholate and laurylsucrose 
enhance the selectivity of the AmB binding to sterols at exactly the concentrations of the 
surfactants which induce the monomerization of the antibiotic, while the maximal selectivity 
was found at a concentration of the surfactants corresponding to their particular CMC in 
presence of amphotericin B [35].  
Our study is one of the first systematic studies to report on the antileishmanial activity of short 
and medium chain saturated fatty acids. The high reported activity of lauric acid and Labrasol 
against Leishmania parasites can be attributed to their ability to selective permeabilise the cell 
membrane resulting in a rapid and considerable membrane damage and a loss of cellular 
potassium and magnesium [38, 39]. The toxicity of short chain fatty acids that affects both 
membrane fluidity and integrity has been previously reported on certain bacteria like E. coli 
and C. resinae but not against Leishmania spp [38, 39]. The rate and extent of the ion efflux is 
dependent on the chain length of the compounds [38, 39]. Short fatty acid chains mainly in 
their un-dissociated form are more soluble in water that longer chains which are more flexible 
and are able to permeate easier in higher concentrations in the cytoplasmic membrane and 
cause the disorientation of essential membrane components [38]. Also, similar effects on the 
intracellular membrane systems may account for the inhibition of endogenous respiration [38]. 
Similar to our study, lauric acid has previously illustrated dose-dependent inhibition of L. 
infantum, however a comparison with other fatty acids was not available [40]. Similarly, 
Labrasol (a mixed ester of capric and caprylic acid) also illustrated a high antileishmanial 
activity in the nanomolar range, even though Labrasol lacks a clear ionic nature due to the 
shielding effect provided by the polyethylene glycol (PEG) chains and possesses a larger 
hydrophilic head group than lauric acid [41]. It is important to note, that caprylic and capric 
acids are medium-chain saturated fatty acids that account for 65% and 35% of the composition 
of medium-chain triglycerides, which are the sources of abundant and rapidly available energy 
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in the Leishmania parasite [42] especially in the stationary phases of the Leishmania spp. 
Longer chain lipids (stearic acid, tripalmitin), lipid esters (Labrafil) and anionic phospholipids 
(Soy Phosphatidylcholine, Lipoid S100) at tested concentrations did not show activity.  
Short-chain triglycerides (C8) have been reported to exhibit high antimicrobial activity against 
Gram-positive and Gram-negative bacteria which was greater than octanoic acid [43], thus 
commonly using these triglycerides as food preservatives. Better incorporation within the cell 
membrane and the ability to form transient or permanent pores in the membrane or even 
solubilise membranes was reported as possible explanations for this [43, 44]. However, there 
is a large variation in susceptibility among different species of bacteria which can be explained 
by the fact that monocaprylate only integrates in specific regions of the membrane (Ld phase) 
depending on membrane fluidity and phospholipid composition [43]. Lipid phase coexistence 
(mainly Ld, liquid disordered phase and Lo, liquid ordered phase characterised by substantial 
amounts of cholesterol) is a phenomenon of potential biological significance [45, 46]. The 
phase boundaries play a key role in membrane permeabilisation. The interface between two 
lipid phases has a line tension inducing packing defects at the hydrophobic interface of the lipid 
phase and thus, these defects increase membrane permeability [43, 47]. Lipid derivates are 
found to partition strongly into the Ld phases whereas polycyclic aromatic hydrocarbons with 
a flat ring partition preferentially into Lo phases [45]. Lipophosphoglycan (LPG) is one of the 
dominant surface macromolecules of the promastigote stage of all Leishmania parasitic 
species. LPG structural polymorphism has a significant impact on parasite survival but also in 
infectivity both in the sandfly vector and the mammalian host [48]. Monocaprylate can 
incorporate into the Ld phase of the membrane allowing to become more hydrated and thus 
increasing its permeabilisation [43]. The different abilities of monocaprylate to intercalate 
within the cellular membrane can partly explain the observed variability in the in vitro activity 
of lauric acid and Labrasol against all Leishmania spp. 
In addition, short and medium chain fatty acids do not only possess a direct antileishmanial 
activity, but can also modulate the efficacy of other antileishmanial drugs altering the binding 
of the drugs with the sterols of the protozoa membrane. One of the major limitations of 
amphotericin B is a direct result of the binding of the drug to both cholesterol of mammalian 
cells as well as ergosterol of the fungal cells leading to death cell [49]. Some surfactants such 
as sucrose monolaurate have been previously shown to selectively decrease the binding of the 
amphotericin B to cholesterol without interfering with its binding to ergosterol reducing its 
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toxicity and consequently, enhancing its therapeutic index [50]. However, in our study we have 
not tested this.  
Non-ionic surfactants/amphiphiles of medium and longer fatty acid chains such as Tween 80 
(Polyethylene glycol sorbitan monooleate) did not show significant activity while, polysorbate 
20 (Tween 20), possesses a low SI. Although both are commonly included as a non-ionic 
surfactant to kinetically stabilise nanoparticulate formulations such as solid lipid nanoparticles 
they are not ideal to be present on the surface of particulate carriers for delivery of 
antileishmanial drugs.  
Results from this study can guide Quality by Design (QbD) studies towards development of 
novel dosage forms with enhanced antileishmanial activity of existing drugs and an improved 
safety profile.  Amphotericin B remains the first line therapy for VL due to its high efficacy 
and lack of resistance. Thus, selecting excipients that can enhanced AmB’s oral poor aqueous 
solubility and permeability across biological barriers will only result in novel medicines with 
enhanced capability. Our results can help optimise novel strategies under research in this 
respect such as lipidic nanomedicines [51] or oral self-micro/nanoemulsifying drug delivery 
systems (SMEDDS/SNEDDS) [52, 53] such as the proposed SMEDDS (iCo-010 prepared 
from Glyceryl monooleate (Peceol), lauroyl macrogol-32 glyceride (Gelucire 44/14) and d-
alpha tocopheryl polyethylene glycol 1000 succinate (VitE-TPGS) under research for an oral 
AmB formulation. The latter formulations are increasingly receiving interest due to their cost-
effective ease of manufacture and scalability, ability to be converted from a colloidal into a 
solid dosage form with enhanced oral permeability and thermal stability [54]. Short and 
medium chain fatty acids as excipients are increasingly included within formulations of poorly 
soluble as well as peptide/protein drugs to increase their oral bioavailability [55-59], as well 
their capacity to inhibit the P-glycloprotein in the intestine which limits the oral bioavailability 
of many drugs [60].  
Additionally, it is generally suggested that the C12 and C14 hydrophobic chains have an 
optimal balance of partition co-efficient and affinity for the skin [61-63], with the permeation 
enhancing effects for saturated fatty acids sharply increasing up to 11 carbons and reducing 
with increasing chain length [64, 65]. In addition, ionic surfactants are good permeation 
enhancers across the stratum corneum layer which facilitates the accessibility of the drug to the 
parasite foci commonly located at the dermis level [66]. Thus, an ideal excipient for both oral 
and transcutaneous administration needs to be an amphiphile of a short or medium fatty acid 
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chains (such as lauric (C12), capric (C10) or caprylic acid (C8) or their esters) with a polar 
head group that is ideally charged (such as a quaternary ammonium group). Our recent results 
as well as our previous in vitro and in vivo studies using a novel chitin derived pharmaceutical 
amphiphile (N-palmitoyl-N-monomethyl-N,Ndimethyl-N,N,N-trimethyl-6-O-glycolchitosan 
(quaternary ammonium palmitoyl glycol chitosan—GCPQ) support this [9].  
4. Conclusions 
Excipients are used for many different purposes in formulations such as API stabilisation, 
solubilisation, complexation or encapsulation in micro/nanoparticulate or micellar systems, 
with amphiphilic molecules widely used to facilitate wetting or emulsificaiton. Selection of 
generally regarded as safe excipients, that can ensure solubilisation, permeability across 
biological membranes without enhanced toxicity, can potentiate the effects of the drug within 
the final dosage form and allow its rapid progression in clinical trials,  in order to meet the need 
for safer, efficacious, patient compliant drugs for the treatment of neglected tropical diseases 
such as leishmaniasis. Identification of optimal drug-excipient combinations can only result in 
better therapies and we propose the use of short and medium chain amphiphiles (≤12 C) as a 
first point of contact for any formulator for a non-invasive treatment for leishmaniasis.  
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Figures: 
 
 
Figure 1. Chemical structure of marketed antileishmanial drugs. 
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Table 1. Chemical structure and characteristics of selected excipients: phospholipids, lipids and steroids. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials 
Trade name 
(Company) 
Molecular 
Weight 
(g/mol) 
Charge / 
Neutral 
Chemical structure Ref 
Phospholipids 
Soybean Lecithin 
(Phosphatidylcholine), 
C18:2 
Lipoid® S 100 
(Lipoid GmbH) 
800 Anionic 
 
[67] 
1,2-dioleoyl-3-trimethylammonium 
propane, chloride salt, 
C18:1 
DOTAP – CL 
(Avanti® Polar 
Lipids) 
698.5 Cationic 
 
[68] 
1,2-distearoyl-sn-glycero-3-
phosphoethanolamine, N-[methoxy-
(polyethylene glycol)-2000], ammonium 
salt, C18:0- PEG2000 
18:0 PEG2000 PE 
(Avanti® Polar 
Lipids) 
2805.5 
Anionic- 
Pegylated 
 
[69] 
Lipids 
Lauric acid, C12:0 (Sigma-Aldrich) 200.3 Non-ionic 
 
[70] 
Tripalmitin, C16:0 (Acros OrganicsTM) 807.32 Non-ionic 
 
[70] 
Stearic acid, C18:0 (Sigma-Aldrich) 284.5 Non-ionic 
 
[70] 
Steroids 
Cholesterol (Sigma-Aldrich) 386.7 Non-ionic 
 
[70] 
α-Tocopherol  
(DL-α-racemic mixture) 
(Sigma-Aldrich) 472.7 Non-ionic 
 
[70] 
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Table 2. Chemical structure and characteristics of selected excipients: polysaccharides, protein carriers and wetting agents. 
Materials Trade name (Company) 
Molecular Weight 
(g/mol) 
Charge  Chemical structure Ref 
Polysaccharides 
β-Cyclodextrin 
Cavamax® W7  
(Wacker Chemie AG) 
1135 Non-ionic 
 
[71] 
 
2- Hydroxypropyl- β- Cyclodrextrin 
Cavasol® W7 HP  
(Wacker Chemie AG) 
1460 Non-ionic 
 
[72] 
γ-Cyclodextrin 
Cavamax® W8 
(Wacker Chemie AG) 
2805.5 Non-ionic 
 
[71] 
Glycol Chitosan 
(High molecular weight – 30 kDa) 
GC2 (Dr A Lalatsa) 28,427 ± 3,425 Cationic 
 
[14] 
Glycol Chitosan 
(Medium molecular weight – 10 kDa) 
GC24 (Dr A Lalatsa) 9.075 ± 1.485 Cationic [14] 
Glycol Chitosan 
(Low molecular weight – 5 kDa) 
GC48RD9 (Dr A Lalatsa) 4197 ± 1039 Cationic [14] 
Protein carriers 
Human serum albumin (20%) (Grifols) 66,563 - 
 
[73, 74] 
Wetting agents 
Glycerol 
(1,2,3-Propanetriol or Glycerin) 
(Sigma- Aldrich) 92.1 Non-ionic 
 
[70] 
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Table 3. Chemical structures and characteristics of selected amphiphiles. Micellar particle size measured by dynamic light scattering at the concentration 
of 100 mg/ml. Key: NA, data non-available. 
 
Materials 
Trade name 
(Company) 
Molecular Weight 
(g/mol) 
Charge  Composition/  Chemical structure 
CMC in 
water at 
25⁰C  
Micelle 
size (nm) 
HLB 
value 
Ref 
Amphiphiles - Polyethylene glycol esters 
Caprylocaproyl macrogol-8 
glycerides  
(PEG400 -8-Caprylic/Capric 
Glycerides)  
Labrasol® 
(Gattefosse) 
Mixture of mono-, di-, 
and triglycerides and 
mono- and di-fatty 
acid esters of PEG 
Non-ionic 
X= 8 & R= 
Caproic acid (C6): < 2% 
Caprylic acid (C8): 50–80% 
Capric acid (C10): 20-50% 
Lauric acid (C12): < 3% 
Myristic acid (C14): <1%  
 
 
0.0123 % 10.3 12 
[75-
77] 
Oleoyl macrogol-6 glycerides 
(PEG300-6-Oleate) 
 
Labrafil® 
M1944CS 
(Gattefosse) 
Mixture of mono-, di-, 
and triglycerides and 
mono- and di-fatty 
acid esters of PEG 
Non-ionic 
X= 6 & R= 
Palmitic acid (C16): 4-9% 
Stearic acid (C18): < 6% 
Oleic acid (C18:1): 58-80% 
Linoleic acid (C18:2): 15-35% 
Linolenic acid (C18:3): < 2% 
Arachidic acid (C20): < 2% 
Eicosenoic acid (C20:1): < 2% 
NA 176.5 9  
[77, 
78] 
Macrogol 15-hydroxystearate 
(PEG 660 – 12-hydroxystearate) 
Solutol® HS15 
(BASF) 
344.5 / 963.2 Non-ionic 
Mixtures of polyglycol of 
mono- and di-esters of 12-
hydroxystearic acid (about 
70%) and free polyethylene 
glycol (about 30%) 
 
0.005-
0.02% 
9.6 14-16 
[79-
82] 
Amphiphiles – Ionic surfactants 
Hexadecyl trimethyl ammonium 
bromide  
CTAB 
(Sigma-Aldrich) 
364.45 Cationic 
 
0.9 – 1 
mM 
NA 10 
[83-
85] 
Sodium deoxycholate (Sigma-Aldrich) 414.6 Anionic 
 
2 – 6 mM NA 16 
[86, 
87] 
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Table 3 Continuation. Chemical structures and characteristics of selected polymeric excipients. Key: NA, non-available. 
 
Materials 
Trade name 
(Company) 
Molecular Weight 
(g/mol) 
Charge  Composition/  Chemical structure 
CMC in 
water at 
25⁰C  
Micelle 
size (nm) 
HLB 
value 
Ref 
Polymers and amphiphilic polymers  
Polysorbate 20 
(Polyoxyethylene 20 sorbitan 
monolaurate) 
Tween® 20 
(Panreac) 
1228 Non-ionic 
 
0.011- 0.05 
mM 
NA 16.7 
[88, 
89] 
Polysorbate 80 
(Polyoxyethylene 20 sorbitan 
monooleate) 
Tween® 80 
(Panreac) 
1310 Non- ionic 
 
0.012- 0.018 
mM 
NA 15 
[88, 
90] 
Polyvinyl caprolactam-polyvinyl 
acetate polyethyleneglycol graft 
copolymer 
 
Soluplus® 
(BASF) 
90,000-140,000 Non-ionic 
Vinyl caprolactam : 57% 
Vinyl acetate : 30% 
PEG 6000:  13% 
 
0.00076 % 55.5 14 
[91, 
92] 
Poloxamer 407 
Poly(ethyleneoxide)/poly-
(propyleneoxide/poly(ethyleneoxide) 
triblock-copolymers 
Pluronic®- F127 
(BASF) 
12,500 
 
Non-ionic 
Ethyleneoxide units: 200 
Propyleneoxide units: 65 
 
0.26 - 0.8% 8.9 22 
[93, 
94] 
Dimethylaminoethyl metacrylate 
Eudragit® E100 
(Evonik) 
47,000 Cationic 
 
NA NA NA [95] 
W+Y+Z=20 
W+Y+Z=20 
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Table 4. Chemical structures and characteristics of solubilisers and solvents. Key: NA, non-applicable. 
 
 
 
 
 
 
 
Poly(methacylic acid-co-methyl 
methacrylate) 1:1  
Eudragit® L100 
(Evonik) 
125,000 Anionic 
 
NA NA NA [95] 
Materials 
Trade name 
(Company) 
Molecular Weight 
(g/mol) 
Charge Composition/ Chemical structure Ref 
Solubilisers 
Polyethylene glycol 400 (Panreac) 380- 420 Non-ionic 
 
[70] 
Polyethylene glycol 6000 (Panreac) 570- 630 Non-ionic 
 
[70] 
Solvents 
Diethylene glycol monoethyl ether 
Transcutol® P 
(Gattefosse) 
134 Non-ionic 
 
[96] 
Isopropyl myristate (Panreac) 270.47 Non-ionic 
 
[70] 
Dichloromethane (Sigma- Aldrich) 84.9 Non-ionic 
 
[70] 
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Table 5. Leishmanicidal activity of selected excipients on extracellular forms (L. amazonensis, L. braziliensis and L. donovani) and cytotoxicity on J774 
macrophages. Cytotoxicity on macrophages was only determined for those excipients that showed activity against Leishmania parasites. Key: NA, non-active at the highest tested concentration 
(200 µg/ml); NC, non-cytotoxic at the highest tested concentration (200 µg/ml);  IC50, concentration of the excipient that produced a 50% reduction in parasites; CC50, concentration of the 
excipient that produced a 50% reduction of cell viability in treated culture cells with respect to untreated ones; GI(%), percentage of inhibition at the highest tested concentration (200 µg/ml); SI, 
selectivity index calculated as CC50/IC50; MW, molecular weight; GC, glycol chitosan. Molecular weight of Labrasol was calculated based on the specification of the US Pharmacopeia where it 
is stated that the mean relative molecular weight is between 200 and 400 g/mol [97]. The calculated molecular weight of Solutol HS15 was 655.7 g/mol which cobtained taking into account 30% 
of free polyethylene glycol 660 (MW= 660 g/mol) and 70% of an equal mixture of polyglycols of mono- and di-esters of 12-hydroxystearic acid (MW= 644.5 and 963.2 g/mol).  
Excipient 
L. amazonensis L. braziliensis L. donovani J774 
GI (%) IC50 (µM) SI GI (%) IC50 (µM) SI GI (%) IC50 (µM) SI CC50 (µM) 
Phospholipids 
Soybean Lecithin 
(Lipoid S100) 
0 NA - 0 NA - 0 NA - - 
DOTAP – CL 84,14% 101.73  ± 0,68 1.48 77,3% 244.6 ± 0,46 0.61 0 NA - 151.44 ± 28.53 
18:0 PEG2000 PE 0 NA - 0 NA - 0 NA - - 
Lipids 
Lauric acid, C12:0 95,24% 136.64 ± 4.64 3.48 100% 30.35 ± 5.64 14.1 95.5% 161  ± 13 2.65 426.86 ± 17.8 
Tripalmitin, C16:0 0 NA - 0 NA - 0 NA - - 
Stearic acid, C18:0 0 NA - 39,6% NA - 0 NA - NC 
Steroids 
Cholesterol 0 NA - 0 NA - 0 NA - - 
α-Tocopherol 0 NA - 0 NA - 0 NA - - 
Sodium deoxycholate 98,5% 134.7 ± 13.55 2.58 97,8% 133.55 ± 42.4 2.59 96.25% 77.37  ± 8.65 4.48 347.1 ± 21.1 
Polysaccharides 
β-Cyclodextrin 0 NA - 0 NA - 0 NA - - 
2- HP β- Cyclodrextrin 0 NA - 0 NA - 0 NA - - 
γ-Cyclodextrin 0 NA - 0 NA - 0 NA - - 
GC (High MW) 0 NA - 0 NA - 0 NA - - 
GC (Medium MW) 0 NA - 0 NA - 0 NA - - 
GC (Low MW) 0 NA - 0 NA - 0 NA - - 
Proteins 
Human serum albumin 0 NA - 0 NA - 0 NA - - 
Wetting agents 
Glycerol 0 NA - 0 NA - 0 NA - - 
Amphiphiles- Polyethylene glycol esters 
Labrasol® 70,5% 271.3 – 546.2  3.28 74,1% 111.7- 223.4 7.98 93.07% 68.9 - 137.95  12.9 891.6 – 1.783  
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Labrafil® M1944CS 0 NA - 0 NA - 0 NA - - 
Solutol® HS15 20,39% NA - 81,2% 102.3 ± 21.6 25.6 61.67% 152.7  ± 38.4 17.2 2618.6 ± 175.1 
Amphiphiles- Triblock copolymers 
Soluplus® 0 NA - 0 NA - 0 NA - - 
Pluronic®- F127 0 NA - 0 NA - 0 NA - - 
Amphiphiles - Polyethylene sorbitol esters 
Tween® 20 33,32% NA - 41,83% 250.2 ± 63.1 0.21 75.8% 123.53 ± 12.19 0.44 54.58 ± 11.07 
Tween® 80 0 NA - 0 NA - 0 NA - - 
Amphililes- ionic surfactant 
CTAB 97,8% 8.53 ± 0,30 11.1 100% 6.44 ± 0,05 14.6 96.8% < 4.28 > 22 94.39 ± 10.43 
Poly(meth)acrylates 
Eudragit® E100 97% 1.92 ± 0.2 - 90,63% 1.69  ± 0.09 - 97.2% 0.42  ± 0.06 -[KL2] NC 
Eudragit® L100 0 NA - 0 NA - 0 NA - - 
Solubilisers 
PEG400 0 NA - 0 NA - 0 NA - - 
PEG-600 
0 NA - 0 NA - 0 NA - - 
Solvents 
Transcutol® 0 NA - 0 NA - 0 NA - - 
Isopropyl myristate 0 NA - 0 NA - 0 NA - - 
Dichloromethane 0 NA - 0 NA - 0 NA - - 
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